Table 3.
Subgroup analyses of PLR for OS and DFS
| Subgroups | Independent cohorts | Sample size | HR* (95% CI) (H/L*) | P value | Study heterogeneity | |||
|---|---|---|---|---|---|---|---|---|
| χ 2 | df* | I 2, % | P value | |||||
| Overall survival | 12 | 6930 | 1.32 (1.11‐1.57) | 0.002 | ||||
| Pathology | ||||||||
| Triple‐negative | 4 | 727 | 1.54 (1.03‐2.33) | 0.04 | 9.65 | 3 | 69 | 0.02 |
| Her2‐positive | 5 | 894 | 1.18 (0.83‐1.70) | 0.36 | 9.70 | 4 | 59 | 0.05 |
| Cut‐off value | ||||||||
| <185 | 6 | 3928 | 1.09 (0.97‐1.22) | 0.15 | 3.94 | 5 | 0 | 0.56 |
| ≥185 | 6 | 3002 | 1.81 (1.33‐2.46) | 0.0001 | 14.04 | 5 | 64 | 0.02 |
| Tumor progression | ||||||||
| Early‐stage | 6 | 2209 | 1.26 (0.97‐1.63) | 0.08 | 11.83 | 5 | 58 | 0.04 |
| Metastatic | 2 | 211 | 1.69 (1.27‐2.27) | 0.0004 | 0.14 | 1 | 0 | 0.71 |
| Geographical region | ||||||||
| Asia | 6 | 3075 | 1.14 (1.02‐1.28) | 0.02 | 5.23 | 5 | 4 | 0.39 |
| America | 4 | 3051 | 1.89 (1.13‐3.14) | 0.01 | 17.88 | 3 | 83 | 0.0005 |
| Europe | 2 | 804 | 1.70 (1.10‐2.62) | 0.02 | 0.25 | 1 | 0 | 0.62 |
| Disease‐free survival | 11 | 5013 | 1.43 (1.09‐1.86) | 0.009 | 44.24 | 10 | 77 | <0.0001 |
| Pathology | ||||||||
| Triple‐negative | 1 | 161 | 1.40 (0.97‐2.00) | 0.07 | NA | NA | NA | NA |
| Her2‐positive | 3 | 406 | 0.74 (0.42‐1.31) | 0.30 | 5.75 | 2 | 65 | 0.06 |
| Cut‐off value | ||||||||
| <185 | 6 | 1936 | 1.28 (0.99‐1.66) | 0.06 | 10.03 | 5 | 50 | 0.07 |
| ≥185 | 5 | 3077 | 1.63 (0.86‐3.07) | 0.13 | 32.74 | 4 | 88 | <0.0001 |
| Geographical region | ||||||||
| Asia | 9 | 4094 | 1.28 (0.98‐1.68) | 0.07 | 34.19 | 8 | 77 | <0.0001 |
| America | 1 | 172 | 4.13 (1.60‐10.66) | 0.003 | N/A | N/A | N/A | N/A |
| Europe | 1 | 747 | 2.02 (1.18‐3.46) | 0.01 | N/A | N/A | N/A | N/A |
Abbreviations: CI*, confidence interval; df*, degrees of freedom; HR, Hazard Ratio; H, High group, L, Low group; N/A, not available.
The bolds represent summary of subgroup analyses for OS and DFS.